- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 19.08. | Prenetics Global Ltd - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 19.08. | Prenetics Global Limited: Prenetics Announces Acquisition of Europa Sports Partners in Strategic Expansion to Consumer Health and Wellness Industry | 1 | GlobeNewswire (USA) | ||
| 12.07. | Prenetics partners with David Beckham for new health brand | 1 | TechNode | ||
| 12.07. | US health sciences company Prenetics partners with David Beckham for new health brand | 1 | TechNode | ||
| 11.07. | Renowned Footballer David Beckham Invests In Small Health & Wellness Firm Prenetics | 1 | Benzinga.com | ||
| 11.07. | Prenetics Global Limited: Prenetics, NASDAQ Health Sciences Company, Partners with David Beckham | 349 | GlobeNewswire (Europe) | Beckham becomes a strategic investor in PreneticsBeckham and Prenetics are co-founding partners for IM8, a new health and wellness brand LOS ANGELES, July 11, 2024 (GLOBE NEWSWIRE) -- Prenetics... ► Artikel lesen | |
| 11.07. | Prenetics Global Ltd - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 01.07. | Prenetics Global Limited: Prenetics Welcomes Kathyrn M. Henry and David Vanderveen to Board of Directors | 1 | GlobeNewswire (USA) | ||
| 18.06. | Prenetics Global Limited: Prenetics Announces First Quarter 2024 Financial Results | 148 | GlobeNewswire (Europe) | First Quarter Revenue Increased 30.2% and Gross Profit Increased 159.8% from Prior Year Quarter Confirms Strategic Pivot Targeting the U.S. Consumer Healthcare Market Reaffirms 2024 Revenue Range... ► Artikel lesen | |
| 18.06. | Prenetics Global Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 20.05. | Prenetics Global Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 02.04. | Prenetics Global GAAP EPS of -$1.49, revenue of $5.43M | 1 | Seeking Alpha | ||
| 01.04. | Prenetics Global: Q4 Earnings Insights | 1 | Benzinga.com | ||
| 01.04. | Prenetics Flat on Financial Results | - | Baystreet.ca | ||
| 01.04. | Prenetics Global Ltd - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 01.04. | Prenetics Global Limited: Prenetics Announces Fourth Quarter and Full Year 2023 Financial Results | 185 | GlobeNewswire (Europe) | HONG KONG, April 01, 2024 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) ("Prenetics" or the "Company"), a leading genomics-driven health sciences company, today announced unaudited financial... ► Artikel lesen | |
| 20.11.23 | Prenetics Global Limited: Prenetics Announces Third Quarter 2023 Financial Results | 304 | GlobeNewswire (Europe) | HONG KONG, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) ("Prenetics" or the "Company"), a leading genomics-driven health sciences company, today announced financial results... ► Artikel lesen | |
| 01.11.23 | Prenetics Global Limited: Prenetics Global Limited Announces Reverse Stock Split | 217 | GlobeNewswire (Europe) | HONG KONG, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE), a leading-genomics-driven health sciences company today announced that it will proceed with a reverse stock split... ► Artikel lesen | |
| 15.09.23 | Prenetics Global Limited: Prenetics Announces Second Quarter 2023 Financial Results | 488 | GlobeNewswire (Europe) | HONG KONG, Sept. 15, 2023 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) ("Prenetics" or the "Company"), a leading genomics-driven health sciences company, today announced financial results... ► Artikel lesen |
19 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QUANTUM-SI | 0,920 | +1,51 % | Quantum-Si Reports Second Quarter 2024 Financial Results | BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Incorporated (Nasdaq: QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing Company, today announced financial results for the second... ► Artikel lesen | |
| SCILEX | 1,030 | -7,21 % | Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, and Denali Capital Acquisition Corp. (Nasdaq: DECA) Announce Signing of a Merger Agreement for a proposed Business Combination, Providing for a Pre-Transaction Equity Value | Semnur Pharmaceuticals, Inc. ("Semnur"), a wholly owned subsidiary of Scilex Holding Company (Nasdaq: SCLX, "Scilex"), and Denali Capital Acquisition Corp. (Nasdaq: DECA, the "SPAC") announce the... ► Artikel lesen | |
| QIAGEN | 39,955 | -0,73 % | Qiagen will neue Wandelanleihen ausgeben | Qiagen kündigt die Emission von Wandelanleihen an. Die Emission soll ein Gesamtvolumen von bis zu 450 Millionen Dollar haben, so das Unternehmen am Dienstag. Die Anleihe wird in einer Stückelung von... ► Artikel lesen | |
| EVOTEC | 5,940 | -2,14 % | Evotec, HelloFresh, nucera, TUI, Vonovia - 4investors Aktien Top-News | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
| DYNE THERAPEUTICS | 33,040 | -1,81 % | Dyne Therapeutics Reports Positive Data From Phase 1/2 DELIVER Trial Of DYNE-251 In DMD | WASHINGTON (dpa-AFX) - Tuesday, Dyne Therapeutics, Inc. (DYN) revealed new clinical findings from its Phase 1/2 DELIVER trial of DYNE-251 for patients with Duchenne muscular dystrophy also known... ► Artikel lesen | |
| NUVALENT | 86,25 | +1,52 % | Nuvalent stock retains Overweight rating as Barclays focuses on Phase 1 ROS1 data at ESMO | ||
| BIONTECH | 81,45 | +0,37 % | Bayer, Vidac Pharma, BioNTech - Healthcare Sektor vor einer Renaissance | In den letzten Monaten zeigen sich verheißungsvolle Anzeichen für eine Renaissance des Healthcare-Sektors. Innovative Start-ups treiben trotz Investitionsrückgängen die digitale Transformation voran... ► Artikel lesen | |
| IMMUNOVANT | 34,030 | +1,22 % | Immunovant Inc.: Immunovant to Host Graves' Disease Program Update on September 9, 2024 | ||
| TARSUS PHARMACEUTICALS | 30,650 | +12,23 % | Tarsus Pharmaceuticals, Inc: Tarsus Reports First Quarter 2024 Financial Results and Recent Business Achievements | Generated $24.7 million in net product sales of XDEMVY®, an 89% increase over Q4 2023, and delivered approximately 26,000 bottles of XDEMVY to patients Secured multiple commercial payer contracts... ► Artikel lesen | |
| ADMA BIOLOGICS | 16,250 | -3,04 % | Adma biologics executive trades shares worth over $400,000 | ||
| BAVARIAN NORDIC | 31,410 | -0,25 % | AKTIONÄR-Depotwert Bavarian Nordic: UNICEF mit Paukenschlag | Die Ausbreitung von Mpox in Afrika bereitet Experten weiterhin Sorgen. Um das Problem in den Griff zu bekommen, hat das UN-Kinderhilfswerk UNICEF in mehreren Ländern eine Notfallausschreibung für Mpox-Impfstoff... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 12,290 | -1,68 % | Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2024 | MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on its operational progress for the... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 5,915 | -4,13 % | Recursion Pharmaceuticals, Inc.: Recursion Announces Phase 2 Data of REC-994, a First-in-Disease Investigational Treatment for Symptomatic Cerebral Cavernous Malformation (CCM), has Met its Primary Endpoint of Safety and Tolerability | REC-994 also demonstrates encouraging trends in objective MRI-based exploratory efficacy measures at the highest dose and the company plans to advance development of REC-994 for the potential treatment... ► Artikel lesen | |
| CG ONCOLOGY | 38,020 | +1,22 % | CG Oncology director sells over $23 million in company stock | ||
| BB BIOTECH | 39,100 | -2,62 % | BB Biotech: Vom neuen Sektor-Aufschwung profitieren | Die Anzeichen einer neuen Biotech-Hausse verdichten sich. Immer mehr Profis positionieren sich für eine längerfristige Sektor-Rallye. Cleveres Stockpicking ist jetzt entscheidend. Alternativ setzen... ► Artikel lesen |
PRENETICS GLOBAL LIMITED gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -0,21 % bei einem Aktienkurs von 4,710 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PRENETICS GLOBAL LIMITED finden Sie auf Wallstreet Online.
